G

Glenmark Pharmaceuticals Ltd
NSE:GLENMARK

Watchlist Manager
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Watchlist
Price: 1 478.2 INR 0.69% Market Closed
Market Cap: 417.1B INR
Have any thoughts about
Glenmark Pharmaceuticals Ltd?
Write Note

Intrinsic Value

The intrinsic value of one GLENMARK stock under the Base Case scenario is 1 029.95 INR. Compared to the current market price of 1 478.2 INR, Glenmark Pharmaceuticals Ltd is Overvalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GLENMARK Intrinsic Value
1 029.95 INR
Overvaluation 30%
Intrinsic Value
Price
G
Worst Case
Base Case
Best Case

Valuation Backtest
Glenmark Pharmaceuticals Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GLENMARK cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GLENMARK?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Glenmark Pharmaceuticals Ltd

Provide an overview of the primary business activities
of Glenmark Pharmaceuticals Ltd.

What unique competitive advantages
does Glenmark Pharmaceuticals Ltd hold over its rivals?

What risks and challenges
does Glenmark Pharmaceuticals Ltd face in the near future?

Has there been any significant insider trading activity
in Glenmark Pharmaceuticals Ltd recently?

Summarize the latest earnings call
of Glenmark Pharmaceuticals Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Glenmark Pharmaceuticals Ltd.

Provide P/S
for Glenmark Pharmaceuticals Ltd.

Provide P/E
for Glenmark Pharmaceuticals Ltd.

Provide P/OCF
for Glenmark Pharmaceuticals Ltd.

Provide P/FCFE
for Glenmark Pharmaceuticals Ltd.

Provide P/B
for Glenmark Pharmaceuticals Ltd.

Provide EV/S
for Glenmark Pharmaceuticals Ltd.

Provide EV/GP
for Glenmark Pharmaceuticals Ltd.

Provide EV/EBITDA
for Glenmark Pharmaceuticals Ltd.

Provide EV/EBIT
for Glenmark Pharmaceuticals Ltd.

Provide EV/OCF
for Glenmark Pharmaceuticals Ltd.

Provide EV/FCFF
for Glenmark Pharmaceuticals Ltd.

Provide EV/IC
for Glenmark Pharmaceuticals Ltd.

Show me price targets
for Glenmark Pharmaceuticals Ltd made by professional analysts.

What are the Revenue projections
for Glenmark Pharmaceuticals Ltd?

How accurate were the past Revenue estimates
for Glenmark Pharmaceuticals Ltd?

What are the Net Income projections
for Glenmark Pharmaceuticals Ltd?

How accurate were the past Net Income estimates
for Glenmark Pharmaceuticals Ltd?

What are the EPS projections
for Glenmark Pharmaceuticals Ltd?

How accurate were the past EPS estimates
for Glenmark Pharmaceuticals Ltd?

What are the EBIT projections
for Glenmark Pharmaceuticals Ltd?

How accurate were the past EBIT estimates
for Glenmark Pharmaceuticals Ltd?

Compare the revenue forecasts
for Glenmark Pharmaceuticals Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Glenmark Pharmaceuticals Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Glenmark Pharmaceuticals Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Glenmark Pharmaceuticals Ltd compared to its peers.

Compare the P/E ratios
of Glenmark Pharmaceuticals Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Glenmark Pharmaceuticals Ltd with its peers.

Analyze the financial leverage
of Glenmark Pharmaceuticals Ltd compared to its main competitors.

Show all profitability ratios
for Glenmark Pharmaceuticals Ltd.

Provide ROE
for Glenmark Pharmaceuticals Ltd.

Provide ROA
for Glenmark Pharmaceuticals Ltd.

Provide ROIC
for Glenmark Pharmaceuticals Ltd.

Provide ROCE
for Glenmark Pharmaceuticals Ltd.

Provide Gross Margin
for Glenmark Pharmaceuticals Ltd.

Provide Operating Margin
for Glenmark Pharmaceuticals Ltd.

Provide Net Margin
for Glenmark Pharmaceuticals Ltd.

Provide FCF Margin
for Glenmark Pharmaceuticals Ltd.

Show all solvency ratios
for Glenmark Pharmaceuticals Ltd.

Provide D/E Ratio
for Glenmark Pharmaceuticals Ltd.

Provide D/A Ratio
for Glenmark Pharmaceuticals Ltd.

Provide Interest Coverage Ratio
for Glenmark Pharmaceuticals Ltd.

Provide Altman Z-Score Ratio
for Glenmark Pharmaceuticals Ltd.

Provide Quick Ratio
for Glenmark Pharmaceuticals Ltd.

Provide Current Ratio
for Glenmark Pharmaceuticals Ltd.

Provide Cash Ratio
for Glenmark Pharmaceuticals Ltd.

What is the historical Revenue growth
over the last 5 years for Glenmark Pharmaceuticals Ltd?

What is the historical Net Income growth
over the last 5 years for Glenmark Pharmaceuticals Ltd?

What is the current Free Cash Flow
of Glenmark Pharmaceuticals Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Glenmark Pharmaceuticals Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Glenmark Pharmaceuticals Ltd

Current Assets 74.3B
Cash & Short-Term Investments 18.3B
Receivables 18.6B
Other Current Assets 37.4B
Non-Current Assets 69.3B
Long-Term Investments 8.6B
PP&E 35.4B
Intangibles 13.3B
Other Non-Current Assets 12B
Current Liabilities 58.2B
Accounts Payable 25.4B
Other Current Liabilities 32.8B
Non-Current Liabilities 6.9B
Long-Term Debt 1.5B
Other Non-Current Liabilities 5.4B
Efficiency

Earnings Waterfall
Glenmark Pharmaceuticals Ltd

Revenue
120.2B INR
Cost of Revenue
-43.4B INR
Gross Profit
76.9B INR
Operating Expenses
-69B INR
Operating Income
7.9B INR
Other Expenses
-21B INR
Net Income
-13.1B INR

Free Cash Flow Analysis
Glenmark Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GLENMARK Profitability Score
Profitability Due Diligence

Glenmark Pharmaceuticals Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Positive 3-Years Revenue Growth
Positive Operating Income
37/100
Profitability
Score

Glenmark Pharmaceuticals Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

GLENMARK Solvency Score
Solvency Due Diligence

Glenmark Pharmaceuticals Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Negative Net Debt
Low D/E
Long-Term Solvency
65/100
Solvency
Score

Glenmark Pharmaceuticals Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GLENMARK Price Targets Summary
Glenmark Pharmaceuticals Ltd

Wall Street analysts forecast GLENMARK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GLENMARK is 1 591.11 INR with a low forecast of 575.7 INR and a high forecast of 2 137.8 INR.

Lowest
Price Target
575.7 INR
61% Downside
Average
Price Target
1 591.11 INR
8% Upside
Highest
Price Target
2 137.8 INR
45% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GLENMARK?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for GLENMARK is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

GLENMARK Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Glenmark Pharmaceuticals Ltd

Country

India

Industry

Pharmaceuticals

Market Cap

417.1B INR

Dividend Yield

0.17%

Description

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The firm is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. The company focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. The company is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. The company is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.

Contact

MAHARASHTRA
Mumbai
Glenmark House, HDO Corporate Building, Wing - A, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri - E
+912240189999
glenmarkpharma.com

IPO

1999-12-10

Employees

13 390

Officers

Chairman, MD & CEO
Mr. Glenn Mario Saldanha
Executive Director of Corporate Services & Executive Director
Ms. Cherylann Maria Pinto B.Pharm
Executive Director
Mr. V. S. Mani
Company Secretary & Compliance Officer
Mr. Harish Vinayak Kuber
President and Chief Human Resources Officer
Mr. Alind Sharma
President & Head of Global Pharmaceutical Development
Mr. Ulhas R. Dhuppad
Show More
President & Chief Quality Officer
Mr. Indrajit Bose
President & Global Head of Formulation Operations
Mr. Brijlal Motwani
President & Business Head of India Formulations
Mr. Alok Malik
President and Business Head of Europe & Emerging Markets
Mr. Christoph Stoller
Show Less

See Also

Discover More
What is the Intrinsic Value of one GLENMARK stock?

The intrinsic value of one GLENMARK stock under the Base Case scenario is 1 029.95 INR.

Is GLENMARK stock undervalued or overvalued?

Compared to the current market price of 1 478.2 INR, Glenmark Pharmaceuticals Ltd is Overvalued by 30%.

Back to Top